When the vaccines of AstraZeneca and Johnson & Johnson are in trouble in the United States and the European Union, respectively, Pfizer and BioNTech may be the companies that benefit the most. The vaccine of these two companies entered the market earlier and it has rapid production and distribution capabilities. In the coming months, it may become a potential target for vaccine procurement in many countries.
According to reports, Chinese disease control official in a rare acknowledgement last week that the current domestic vaccines offer low protection against the coronavirus and now under consideration whether use different vaccines from different technical lines for the immunization process. This news may imply that Beijing is considering importing foreign vaccines.
According to Reuters, China is planning to authorize the COVID-19 vaccine developed by Germany's BioNTech by July, the Wall Street Journal reported on Friday, citing people familiar with the matter.
If approved, it would become the first foreign COVID-19 vaccine to be authorized in the country. Chinese officials are reviewing clinical-trial data for the vaccine and are expected to authorize it for domestic use within the next 10 weeks, the report said.
The report also said that Germany's BioNTech can provide 100 million doses of vaccine, but the schedule is uncertain. Anyway, this is a good news for BioNTech and its stock.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.